Post-Sarepta, Art Krieg gets $20M to take a shot at an immuno-oncology Checkmate

John Carroll

A year after getting bounced from a turbulent Sarepta, Art is prepping for his next act in biotech, snatching a failed lead immunology drug from the dying, Zurich-based Cytos Biotechnology and taking a second stab at a near-term success with a new company that will tackle the red-hot immuno-oncology field.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS